Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > I'm in

<< Previous

Bullboard Posts

Next >>

Post by Northforce13on Mar 02, 2021 2:55pm

140 Views

Post# 32696952

I'm in

Bought some today. The company has had problems, as myself and posters have pointed out, but it also has interesting potential and new management, and it's really cheap...

Took a small position, will sit around and see what happens in the future.

GLTA -)

<< Previous

Bullboard Posts

Next >>

Critical materials crisis: Diversifying away from China’s monopoly